Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
NCT ID: NCT07317102
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
152 participants
OBSERVATIONAL
2026-02-28
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
NCT05923827
32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus
NCT00537251
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
NCT00494013
PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro
NCT00540709
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
NCT00653302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OPTIMAL-B study (Omnipod 5 - A French Prospective Multicentric Study in Real World), aims to provide the requisite real-world data on the glycemic control, quality of life, safety, and device usage profiles of users of the Omnipod 5 System during the 12 months after starting using Omnipod 5 in automated mode.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omnipod 5 User
Participation of each patient begins at inclusion and continues until the end-of-study visit, 12 months (± 1 month) following first initiation of automated mode of the Omnipod 5 System
Omnipod 5
The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin.
The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omnipod 5
The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin.
The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient prescribed, less than a year ago, a commercially available confi guration of the Omnipod 5 System using a FreeStyle Libre 2 Plus sensor.
* Patient has never used the Omnipod 5 System prior to inclusion.
* Patient has not objected to the use of their personal data for this study.
* Patient or legal guardian has an email address and mobile phone number.
* Patient (and legal guardians if the patient is a minor) is able to understand study information and Non-Opposition form.
* Patient (and legal guardians if the patient is a minor) is able to understand and complete questionnaires in French.
* Patient is covered by the local social security system
Exclusion Criteria
* Patient presents an allergy to the materials of the Omnipod 5 System (patch, cannula, CGM).
* Patient is unable to be followed by the same investigation site for the duration of the study or is unwilling or unable to maintain contact with the healthcare professional.
* Patient is already participating in a clinical trial or in another study precluding their participation in other studies.
* Adult under guardianship, curatorship or tutorship.
* Adult otherwise deprived of liberty.
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insulet Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Pierre Riveline, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Universitaire du Diabète et ses complications Hôpital Lariboisière
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Angers
Angers, , France
CHU Besançon - Hôpital de Jean Minjoz
Besançon, , France
APHP Hopital Avicenne
Bobigny, , France
CHU Bordeaux - Hôpital Pellegrin
Bordeaux, , France
CHU Bordeaux - Hôpital St-André
Bordeaux, , France
CHU Brest - Hôpital de la Cavale Blanche
Brest, , France
Hôpital Femme Mère Enfant
Bron, , France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, , France
CIRDIA
Dijon, , France
CHU Dijon - Hôpital François Mitterrand
Dijon, , France
GH La Rochelle-Ré-Aunis - Hôpital Saint Louis
La Rochelle, , France
APHP Hôpital Bicêtre
Le Kremlin-Bicêtre, , France
Institut de Diabétologie et de Nutrition du Centre
Mainvilliers, , France
Fondation Ambroise Paré - Hôpital Européen de Marseille
Marseille, , France
CHU Montpellier - Hôpital Lapeyronie
Montpellier, , France
Institut Saint Pierre
Palavas-les-Flots, , France
APHP Hôpital Lariboisière
Paris, , France
APHP Hopital Robert Debré
Paris, , France
CH Périgueux
Périgueux, , France
Clinique Saint Jean de Védas
Saint-Jean-de-Védas, , France
CHRU Strasbourg
Strasbourg, , France
CHU Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lucie DUFOUR
Role: primary
Julie GUCCIARDI
Role: primary
Sarah YAHIAOUI
Role: primary
Caroline BOUYSSOU
Role: primary
Bogdan CATARGI
Role: primary
Pascale Quiniou
Role: primary
Karima RENDJA
Role: primary
Catherine PETIT
Role: primary
Sylvie PICARD
Role: primary
Isabelle SIMONEAU
Role: primary
Harivola ANDRIANTAOLO
Role: primary
Marie-Agathe TROUVIN
Role: primary
Eva BRIAND
Role: primary
Audrey OLIVETTI
Role: primary
Manal AL MASRI-SHBAT
Role: primary
Chrystel LEPERCHOIS
Role: primary
Charline POTIER
Role: primary
Caroline ARNAUD-SARTHOU
Role: primary
Aude ANGELESCU
Role: primary
Mérédith MERCIER
Role: primary
Samir CHENAF
Role: primary
Sophie GOUNIN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Optimal-B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.